Background, Basis of Presentation, Economic Dependency and Significant Accounting Policies: - Basis of Presentation thru Fair Value of Financial Instruments (Details)	12 Months Ended
	Feb. 28, 2023 USD ($) item shares	Feb. 28, 2022 USD ($) shares
Percentage of outstanding stock owned by the President and Chairman of the Board	81.00%
Number of antineoplaston drugs that have received FDA approval | item	0
Economic Dependency
Significant external revenue	$ 0	$ 0
Accumulated deficit	126,754,775	125,838,483
Losses incurred	916,292	976,656
Income Taxes
Uncertain tax positions	$ 0	$ 0
Loss Per Common Share
Shares excluded from calculation of diluted loss per share (in shares) | shares	600,000	1,600,000
Fair Value of Financial Instruments
Number of financial instruments held for trading purposes | item	0
Minimum
Economic Dependency
Estimated useful lives	5 years
Maximum
Economic Dependency
Estimated useful lives	10 years